COUAA202_2 | R Documentation |
Kaplan-Meier digitized data from COUAA202, figure 2 (PMID 25601341). A reported sample size of 1,088 for a primary endpoint of rPFS/OS in prostate cancer.
COUAA202_2
A data frame of 1,088 observations and 3 variables:
time | event time (in months) | |
event | OS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (abiraterone, placebo) | |
Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015; 16: 152–60.
summary(COUAA202_2)
kmplot(COUAA202_2)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.